The Classic eMule new 10 years silence update returns - The rise and popularity of streaming platforms have made P2P platforms have lost strength, but what is clear is that they resist dying and even dare to give any other surprise: the classic eMule, one of the most popular programs of the 2000s has received an update after more than 10 years of silence.

The eMule download program was launched in 2002 and quickly became the most used program in the world to exchange all kinds of files, until the arrival of BitTorrent, which banished it to the background.

The fact is that eMule received its last stable update, the 0.50 a, more than 10 years ago and from that moment it remained silent until it practically went into oblivion.

Classic eMule new 10 years silence update returns

Now, a decade later, one of the community developers has announced a new version, the 0.60 a that promises to bring with IT major changes where they promise security improvements, bug fixes and regressions and for the first time 32-bit and another 64-bit versions.

In addition, it provides support for HTTPS to download the servers.met or the nodes.dat using the program.

However, this is not an official version of the original team of the project, but an update made by the community that offers its free open source to download on SourceForge.

End of Classic eMule new 10 years silence update returns

More on

Three questions about the mysterious reinfections of coronavirus that scientists still can not answer

Since the first cases of coronavirus reinfections were confirmed in various parts of the world, questions about what they may involve have accumulated.

The low number of cases so far does not allow definitive conclusions to be drawn about reinfections, but the increase in re-infections in all countries is expected to increase the number of reinfections and may be further explored.

Nature has compiled the three questions that science will try to solve around coronavirus reinfection.

How common can it be to reinfect?

Information about the possibility of re-infection has been circulating since the pandemic began. Until now, such cases had been ruled out as diagnostic test errors or system persistence of the virus that had caused the first infection.

To confirm the recently reported cases of reinfection, the researchers analyzed the genome of the two viruses and found enough differences to state that they were different infections. However, the scarcity of such samples so far prevents us from knowing how common the phenomenon is.

However, researchers are now at the best time to unravel this question, as enough time has passed since the first infections and the increase in regrowth around the world guarantees that a large part of the population (even if the disease has already passed) will be exposed to the contagion again.

Is the disease milder during the second infection?

The first confirmed case of reinfection occurred in a Hong Kong patient who passed the second infection completely asymptomatic while his first time required hospital admission.

Several experts noted that it was a good sign, since it confirmed that the body acquired some immunity that gave some protection against the disease.

However, a few days later it was reported that a patient from Nevada (United States) was experiencing the disease for the second time with symptoms of greater severity.

Researchers do not know whether the Nevada case will remain an anecdote or whether there might even be a possibility that the immune system will aggravate the infection, as happens in some cases.

What does it involve for Vaccine Development?

The successful development of vaccines depends to a large extent on knowing exactly what the immune response to a disease looks like and clearing questions about how long immunity lasts after re-infection or what type of immune cells are involved.

The ideal scenario for a vaccine to fully protect is to encounter a virus whose infection produces long-term immunity, such as chickenpox, for example.

However, experts consulted by Nature warn that, although it does not appear that this will happen with SARS-Cov - 2, it does not compromise the development of a vaccine candidate. It probably only means vaccines will need a booster dose, which would increase their manufacturing and distribution cost.